The GLP-1 Boom Is Building a Whole New Health Industry Around It

GLP-1 drugs have changed weight loss and diabetes care fast. But that’s only half the story.

Around these medications, a whole support industry has sprung up. Dietitian networks, body scan clinics, addiction treatment startups. All of them are riding the same wave.

Let’s break down what’s happening and why it matters. The FDA approved Wegovy for chronic weight management back in 2021. That’s semaglutide, the same drug found in Ozempic, just approved for a different use. Ozempic was originally cleared for type 2 diabetes. Wegovy opened the door to weight loss as a standalone indication.

Since then, tirzepatide has entered the picture too, sold as Mounjaro. Together, these drugs have pulled in millions of new patients. And that demand hasn’t stayed contained to pharmacies and doctors’ offices.

Telehealth companies noticed first. Nourish, a virtual dietitian network launched in 2021, started out helping people manage chronic conditions like diabetes and digestive issues. Patients worked with registered dietitians remotely.

Then, in early 2026, Nourish made a bigger move. The company began managing GLP-1 prescriptions directly. Why? Because patients kept asking for it.

Nourish says its dietitian-led approach helps patients stick with GLP-1 treatment longer. That’s worth noting, but it’s also company data, not an independent clinical trial. So take it as a promising signal, not a proven fact.

The numbers behind this trend are hard to ignore. J.P. Morgan Global Research estimated that 10 million Americans used GLP-1 drugs in 2025. That’s nearly double the 2023 figure.

Analysts think that number could hit 30 million by 2030. The market itself may reach $200 billion. These are prescription-only medications, though, and the cost isn’t always covered by insurance. That gap raises real questions about who gets access and who gets left out.

Weight loss on GLP-1s isn’t just fat loss, either. Research suggests up to 40 percent of the weight lost can come from muscle mass. That matters more than people realize.

Losing muscle quickly can raise the risk of osteoporosis. So some companies have started offering body composition scans to track what’s actually happening inside a patient’s body, not just the number on the scale.

BodySpec, a DEXA scan provider based in Austin, has seen referrals climb alongside GLP-1 use. More doctors are sending patients in specifically to monitor bone density and lean mass while they’re on these medications. It’s a smart pairing, honestly: medication plus monitoring.

Now researchers are looking even further afield. Scientists are exploring whether GLP-1 drugs could help with addiction, kidney disease, or even neurodegenerative conditions through ongoing clinical trials. None of these uses have FDA approval yet, so they remain off-label territory for now.

One company testing this frontier is Choose Your Horizon, a telehealth provider focused on alcohol use disorder. In 2026, it added GLP-1 medications to its treatment protocol. Sometimes patients get GLP-1s alone. Other times, they’re paired with naltrexone, a drug that’s been used for years to curb alcohol cravings.

The company reports encouraging early results. Still, no peer-reviewed trial has confirmed those outcomes yet. It’s early. Promising, maybe, but early.

All this growth hasn’t gone unnoticed by regulators, either. Off-label prescribing brings up real concerns: long-term safety, insurance coverage, and whether the clinical evidence actually supports these newer uses. Agencies like the CDC and CMS play a role here, one shaping public health guidance, the other shaping what insurance will actually pay for.

So where does this leave things? GLP-1 drugs sparked a wave of innovation that goes way beyond the medication itself. Dietitians, scan clinics, addiction specialists- they’re all adapting to this new reality.

But the science is still catching up to the business growth. More clinical trials are needed before some of these newer applications get formal approval. Until then, expect this space to keep evolving fast, with regulators watching closely every step of the way.